Health Grants
550 open opportunities. Open federal grants funding health, medicine, and public-health work, each with a plain-English eligibility summary, deadline, and award amount.
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
Due Nov 17, 2026National Institutes of Health · Amount varies
The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application.
NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
Due Nov 17, 2026National Institutes of Health · Up to $350K
NIH (NCCIH) R01 funding for multi-site feasibility clinical trials of mind-and-body interventions to prepare for a later full-scale efficacy trial. Intended for research institutions able to coordinate across multiple sites; foreign organizations are not eligible (foreign components allowed). The listed maximum is about $350,000. Sufficient preliminary data from prior single-site work is required, making this narrowly scoped research funding.
ResearchersSchools & universitiesNarrow eligibilityInvestigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
Due Nov 17, 2026National Institutes of Health · Amount varies
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO.
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
Due Nov 18, 2026National Institutes of Health · Amount varies
The purpose of this NOFO is to invite Research Project (R01) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, as well as conceptual, legal, and normative analyses. Direct involvement of key stakeholders where appropriate is encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
Due Nov 18, 2026National Institutes of Health · Amount varies
The purpose of this NOFO is to invite Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, as well as conceptual, legal, and normative analyses. Direct involvement of key stakeholders where appropriate is encouraged. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
Due Nov 19, 2026National Institutes of Health · Amount varies
NIH (NINDS) cooperative-agreement funding (UG3/UH3) for multi-site clinical trials and biomarker studies on stroke prevention, treatment, and recovery, conducted within the NIH StrokeNet infrastructure. Suited to research institutions that will collaborate inside StrokeNet; foreign organizations are not eligible. No specific amount is given. Work must be carried out within StrokeNet and is selected competitively, making this narrow research-only funding.
ResearchersSchools & universitiesNarrow eligibilitySeamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Due Nov 19, 2026National Institutes of Health · Amount varies
NIH cooperative-agreement (UG3/UH3) funding for bundled early-stage (Phase 1 to 2a) clinical drug development of novel therapeutics for Alzheimer's disease and related dementias, focused on non-amyloid/non-tau mechanisms. Intended for research institutions able to run gated, milestone-driven clinical trials. No award amount is stated. This is highly specialized clinical research funding, not suited to individuals or general nonprofits.
ResearchersSchools & universitiesNarrow eligibilityHEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
Due Nov 23, 2026National Institutes of Health · Up to $375K
NIH HEAL Initiative R15 funding for basic or mechanistic pain research at institutions eligible for the R15 (Research Enhancement) mechanism, which targets schools and components that have not been major NIH recipients. Aimed at engaging undergraduate, graduate, and health-professional trainees in the research; foreign organizations are not eligible. The listed maximum is about $375,000. R15 eligibility rules restrict which institutions can apply, so eligibility is narrow.
ResearchersSchools & universitiesNarrow eligibilityCompeting Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
Due Nov 24, 2026National Institutes of Health · Amount varies
NIH mechanism allowing existing award recipients to apply for revision (supplemental) funding to expand a current NIH grant or cooperative agreement, only in response to a specific Notice of Special Interest. Restricted to organizations that already hold an active NIH single-project award. No award amount is specified. Because applicants must already be NIH grantees and respond to a matching NOSI, eligibility is narrow and not open to new applicants.
ResearchersSchools & universitiesNarrow eligibilityNational Center for Construction Safety and Health Research and Translation (U54)
Due Dec 1, 2026Centers for Disease Control and Prevention - ERA · $3M–$5.8M
CDC/NIOSH cooperative-agreement (U54) funding to establish a National Center for Construction Safety and Health Research and Translation. The notice does not list specific applicant types (eligibility marked N/A), but the scope describes a multidisciplinary center led by a qualified research organization, with collaborations from academic and nonprofit partners expected, so confirm eligibility in the full notice. Awards range from about $3,000,000 up to $5,750,000. This is a large, center-scale award; the listed eligibility detail is limited.
ResearchersSchools & universitiesLarge awardMaximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
Due Dec 2, 2026National Institutes of Health · Amount varies
NIH individual postdoctoral fellowship (F32) supporting a named postdoctoral fellow to analyze the ECHO program's longitudinal child-health dataset within the NICHD DASH repository. This is an individual fellowship awarded through a sponsoring US institution; foreign organizations are not eligible and foreign components are not allowed. No award amount is stated. It is restricted to eligible postdoctoral researchers at a US institution, so eligibility is narrow.
ResearchersIndividualsSchools & universitiesNarrow eligibilityEmerging Global Leader Award (K43 Independent Clinical Trial Required)
Due Dec 3, 2026National Institutes of Health · Amount varies
This NIH/Fogarty K43 career development award supports an early-career scientist at an academic or research institution in a low- or middle-income country, with a required independent clinical trial. Eligibility is narrow and country-restricted: only foreign institutions in qualifying LMICs may apply, U.S. organizations and their foreign components are not eligible, and some upper-middle-income G20 countries are excluded. This is not available to U.S. applicants. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityEmerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
Due Dec 3, 2026National Institutes of Health · Amount varies
This NIH/Fogarty K43 career development award supports an early-career scientist at an academic or research institution in a low- or middle-income country, for research that does not involve leading an independent clinical trial. Eligibility is narrow and country-restricted: only foreign institutions in qualifying LMICs may apply, U.S. organizations and their foreign components are not eligible, and some upper-middle-income G20 countries are excluded. This is not available to U.S. applicants. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityNIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
Due Dec 4, 2026National Institutes of Health · Amount varies
This NIH R50 award provides salary support for established Research Software Engineers who build and disseminate biomedical software, tools, and algorithms. Eligible applicants include universities and research institutions; foreign (non-U.S.) organizations are not eligible to apply. It is tied to an existing research environment and specialized staff, so it suits research institutions rather than general nonprofits or individuals applying on their own. No specific award amount is stated.
ResearchersSchools & universitiesBroad eligibilityPrevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
Due Jan 7, 2027National Institutes of Health · Amount varies
This NIH R34 planning grant supports research on prevention and intervention strategies for fetal alcohol spectrum disorders across the lifespan, intended as a precursor to larger studies. Eligible applicants include universities, research institutions, and tribal and community organizations, and foreign organizations are listed among eligible applicants. It is aimed at research teams preparing for larger FASD studies. No specific award amount is stated.
ResearchersSchools & universitiesGovernment / tribalBroad eligibilityMechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Due Jan 7, 2027National Institutes of Health · Amount varies
This NIH R01 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations; a clinical trial is optional. It requires established research capacity in this area. No specific award amount is stated.
ResearchersSchools & universitiesGovernment / tribalBroad eligibilityNHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Due Jan 7, 2027National Institutes of Health · Amount varies
This NIH/NHLBI R61/R33 supports investigator-initiated Phase I clinical trials for therapeutics or diagnostics for heart, lung, blood, and sleep disorders, with the first phase funding final pre-trial preparation. A clinical trial is required. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations. It is aimed at research teams with clinical-trial capacity. No specific award amount is stated.
ResearchersSchools & universitiesGovernment / tribalBroad eligibilityNHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
Due Jan 7, 2027National Institutes of Health · Up to $1.5M
This NIH/NHLBI R33 supports investigator-initiated Phase I clinical trials for therapeutics or diagnostics for heart, lung, blood, and sleep disorders; a clinical trial is required and applicants must be ready to start the trial early. Eligible applicants include universities, research institutions, and tribal and community organizations; foreign organizations are not eligible to apply, though non-U.S. components of U.S. organizations are. The maximum award is about $1.5 million. It requires clinical-trial readiness.
ResearchersSchools & universitiesGovernment / tribalLarge award+1 moreMechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Due Jan 7, 2027National Institutes of Health · Amount varies
This NIH R21 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk; no clinical trial is allowed. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations. It requires research capacity in this area. No specific award amount is stated.
ResearchersSchools & universitiesGovernment / tribalBroad eligibilityAcademic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
Due Jan 7, 2027National Institutes of Health · Up to $375K
This NIH R15 (AREA) award supports small-scale research at undergraduate-focused institutions that receive limited NIH funding, with a required clinical trial. Eligibility is restricted to institutions that award baccalaureate science degrees and have received no more than $6 million/year of NIH support in 4 of the last 7 years; foreign organizations are not eligible to apply. The maximum award is about $375,000. This is narrowly targeted at less-research-intensive degree-granting institutions.
ResearchersSchools & universitiesSmall awardNarrow eligibility